studies

la/mBC - HR-positive - 2nd line (L2), buparlisib plus fulvestrant vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsBELLE-2 (full population), 2017 0.87 [0.74; 1.02] 0.87[0.74; 1.02]BELLE-2 (full population), 201710%1,147NAnot evaluable progression or deaths (PFS)detailed resultsBELLE-2 (full population), 2017 0.78 [0.68; 0.90] BELLE-2 (PI3K pathway activated), 2017 0.76 [0.60; 0.97] 0.77[0.69; 0.88]BELLE-2 (full population), 2017, BELLE-2 (PI3K pathway activated), 201720%1,519lownot evaluable objective responses (ORR)detailed resultsBELLE-2 (full population), 2017 1.60 [1.08; 2.39] BELLE-2 (PI3K pathway activated), 2017 1.34 [0.66; 2.71] 1.54[1.09; 2.17]BELLE-2 (full population), 2017, BELLE-2 (PI3K pathway activated), 201720%1,519lownot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-18 10:10 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1360

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons